8legs: Guggenheim

Your Followed Topics

#1 out of 2

Kyndryl (KD) stock fell after Morgan Stanley cut its price target and Guggenheim downgraded the stock.
Morgan Stanley reduced KD's price target to $13 from $28.
Guggenheim downgraded KD from Buy to Neutral.
Management departures contributed to the downgrade.
Kyndryl disclosed material misstatements and weak internal controls.
The company also disclosed an SEC document request related to cash management.
KD closed the day at $12.39, down 4.4% from the previous close.
Market reaction noted as potentially presenting buying opportunities.
KD has been volatile, with multiple moves of 5% or more this past year.
The article connects oil price trends to broader market moves affecting KD peers.

Vote 0

#2 out of 2

Guggenheim initiates coverage on Generate Biomedicines with a buy rating, signaling institutional interest.
Piper Sandler also starts coverage with a buy rating, expanding the stock's analyst support.
Analysts cite Generate Biomedicines’ pipeline potential as a catalyst for upside.
The news could attract further institutional attention to the company.
Generate Biomedicines is positioned as a potential beneficiary of pharmaceutical industry innovation.
The coverage comes amid broader investor focus on early-stage biotech catalysts.
No clinical data was released in the report, but ratings reflect sentiment.
The article emphasizes market curiosity about Generate Biomedicines’ platform technology.
The report may influence short-term trading as investors reassess risk and reward.
Generate Biomedicines’ shares could react to further broker updates and market visibility.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.